公开(公告)号：US20240358704A1

公开(公告)日：2024-10-31

申请号：US18627727

申请日：2024-04-05

申请人： Hoffmann-La Roche Inc.

发明人： Nicole HELLBACH ,  Heidemarie KLETZL ,  Friedrich METZGER ,  Renata SICILIANI SCALCO

IPC分类号： A61K31/519 ,  A61K9/00 ,  A61K9/08 ,  A61K39/00 ,  A61K39/395 ,  A61P21/00

CPC分类号： A61K31/519 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/08 ,  A61K39/3955 ,  A61P21/00 ,  A61K2039/545

摘要： The invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one, also known as risdiplam, for use in the treatment of spinal muscular atrophy (SMA) with GYM329, its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.

公开(公告)号：US20240358632A1

公开(公告)日：2024-10-31

申请号：US18682785

申请日：2022-05-26

申请人： Ravishankar KOVI ,  Raghu Rami Reddy Kasu ,  Thupalli Ajey Kumar REDDY ,  Yekkanti VAMSHI ,  Jayraman KANNAPPAN ,  Kamlesh CHAUAHAN

发明人： Ravishankar KOVI ,  Raghu Rami Reddy Kasu ,  Thupalli Ajey Kumar REDDY ,  Yekkanti VAMSHI ,  Jayraman KANNAPPAN ,  Kamlesh CHAUAHAN

IPC分类号： A61K9/00 ,  A61K9/08 ,  A61K38/09 ,  A61K47/26

CPC分类号： A61K9/0019 ,  A61K9/08 ,  A61K38/09 ,  A61K47/26

摘要： The present application discloses a ready-to-use liquid parenteral pharmaceutical composition, that has Cetrorelix or Cetrorelix acetate. The composition also has Cetrolix or its pharmaceutically acceptable salt, ethanol, and water for injection, and a pH adjusting agent. The composition may also contain pharmaceutically acceptable excipients. The Cetrolix or Cetrolix acetate preparation can have a pH lower than 7.

公开(公告)号：US12128089B2

公开(公告)日：2024-10-29

申请号：US18202103

申请日：2023-05-25

申请人： Slayback Pharma LLC

发明人： Harish Govindaraja Setty Chinnari ,  Somashekhar Battini ,  Lourdu Chinnu Thippabattuni ,  Satheesh Balasubramanian ,  Sumitra Ashokkumar Pillai ,  Praveen Kumar Subbappa

IPC分类号： A61K38/26 ,  A61K9/00 ,  A61K9/08 ,  A61K47/20 ,  A61K47/26

CPC分类号： A61K38/26 ,  A61K9/0019 ,  A61K9/08 ,  A61K47/20 ,  A61K47/26

摘要： Stable injectable compositions comprising glucagon or a pharmaceutically acceptable salt, solvate, or hydrate thereof are disclosed, which comprise (a) a therapeutically effective amount of glucagon; (b) at least one pharmaceutically acceptable solvent; (c) at least one stabilizing agent; (d) at least one sugar; and (e) optionally, at least one pharmaceutically acceptable excipient; wherein said injectable solution is stable and ready-to-use, and wherein pH of the said solution ranges from 3.8 to 4.2. Preferably, the composition is provided in a sealed container, e.g., an ampoule, a vial, a pre-filled syringe or an auto-injector. Further, stable injectable solutions are disclosed, which comprise glucagon or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and which are suitable for subcutaneous, intravenous or intramuscular administration. Methods for manufacturing stable injectable solutions of glucagon are also disclosed.

公开(公告)号：US12128067B2

公开(公告)日：2024-10-29

申请号：US17297238

申请日：2019-11-25

申请人： YILDIZ TEKNIK UNIVERSITESI ,  Haci Murat Mertoglu

发明人： Haci Murat Mertoglu

IPC分类号： A61K33/10 ,  A61K9/08 ,  A61K33/14 ,  A61K9/00

CPC分类号： A61K33/10 ,  A61K9/08 ,  A61K33/14 ,  A61K9/0043

摘要： The present invention relates to a nasal solution used for elimination of nasal occlusions, for cleaning of the inner section of the nose and for the treatment of nasal diseases, wherein bicarbonate (HCO3−) is provided with weight proportion between 0.05% and 1.50% and carbonate (CO3−2) is provided with weight proportion between 0.05% and 1.50% as the active substance in the ingredient thereof and it has alkali pH characteristic and preferably it is obtained from alkaline, closed basin natural spring waters.

公开(公告)号：US12128011B2

公开(公告)日：2024-10-29

申请号：US17310429

申请日：2020-02-05

申请人： Joseph Halstead

发明人： Joseph Halstead

IPC分类号： A61K47/02 ,  A61K9/08 ,  A61K31/12 ,  A61K47/10 ,  A61K9/00

CPC分类号： A61K31/12 ,  A61K9/08 ,  A61K47/02 ,  A61K47/10

摘要： A method involves dissolving a curcuminoid in glycerol to make an administrable solution. An alkali salt is added to the glycerol to increase the solubility of the curcuminoid in the glycerol to more than 20 milligrams curcuminoid per millilitre of glycerol (and up to in excess of 200 milligrams curcuminoid per millilitre of glycerol with the addition of sufficient alkali salt in embodiments). The resulting administrable solution can be administered (such as by way of intramuscular injection) as is without the need of an aqueous emulsion and can be stored for more titan 24 hours without curcuminoid precipitation.

公开(公告)号：US12128010B2

公开(公告)日：2024-10-29

申请号：US17833836

申请日：2022-06-06

申请人： NOVALIQ GMBH

发明人： Dieter Scherer ,  Ralf Grillenberger ,  Frank Löscher ,  Hartmut Voss

IPC分类号： A61K31/02 ,  A61F9/00 ,  A61K9/00 ,  A61K9/08 ,  A61P27/02

CPC分类号： A61K31/02 ,  A61F9/0008 ,  A61K9/0048 ,  A61K9/08 ,  A61P27/02

摘要： The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.

公开(公告)号：US20240352126A1

公开(公告)日：2024-10-24

申请号：US18688170

申请日：2022-09-02

申请人： DR. REDDY’S LABORATORIES LIMITED

发明人： Murali JAYARAMAN ,  Saisharan K GOUD ,  Sunil Ashok NANKAR ,  Maya NANATH ,  Lovisha AGGARWAL ,  Puja SARKAR ,  Mahesh INGALE ,  Reinhard JACOB ,  Abirami SURESH ,  R. L. Shri Ranga PRIYA ,  Suman LABALA

IPC分类号： C07K16/28 ,  A61K9/08 ,  A61K39/00 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26

CPC分类号： C07K16/2818 ,  A61K9/08 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/94

摘要： The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against human programmed death receptor-1 (PD-1)/programmed death receptor Ligand 1 (PD-L1), and method for preparing the same. The disclosed formulations are free of chelators and stabilizes anti-PD1/anti-PD L1 antibody from lower to higher concentrations rendering it suitable for different modes of administration (subcutaneous/intravenous).

公开(公告)号：US20240342289A1

公开(公告)日：2024-10-17

申请号：US18291846

申请日：2022-08-31

申请人： NITTA GELATIN INC.

发明人： Kazuki KOTANI ,  Yosuke HIRAOKA

IPC分类号： A61K47/42 ,  A61K9/00 ,  A61K9/08

CPC分类号： A61K47/42 ,  A61K9/0019 ,  A61K9/08

摘要： A leakage inhibiting agent includes a gelatin hydrolysate having a weight average molecular weight of 5000 or lees, wherein a degree of viscosity at 25° C. of a first solution obtained by dissolving the gelatin hydrolysate in phosphate buffered saline and adjusting the concentration of the gelatin hydrolysate to 40% by mans is 20 mPa·s or less.

公开(公告)号：US20240342140A1

公开(公告)日：2024-10-17

申请号：US18755647

申请日：2024-06-26

申请人： Chemistry RX

发明人： Lars BRICHTA

IPC分类号： A61K31/436 ,  A61K9/00 ,  A61K9/08 ,  A61K31/506 ,  A61K31/519 ,  A61K31/573 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20

CPC分类号： A61K31/436 ,  A61K9/0014 ,  A61K9/08 ,  A61K31/506 ,  A61K31/519 ,  A61K31/573 ,  A61K47/10 ,  A61K47/12 ,  A61K47/20

摘要： Disclosed herein are liquid compositions and methods for treating hair loss by topical administration of the liquid compositions to a subject in need thereof.

公开(公告)号：US20240342093A1

公开(公告)日：2024-10-17

申请号：US18744878

申请日：2024-06-17

申请人： EUROFARMA LABORATÓRIOS S.A.

发明人： Maurizio BILLI ,  Matheus Marques COSTA ,  Emily Fernanda Freire FOLCO

IPC分类号： A61K9/19 ,  A61K9/08 ,  A61K45/06

CPC分类号： A61K9/19 ,  A61K9/08 ,  A61K45/06

摘要： The present invention refers to parenterally administered pharmaceutical compositions comprising non-steroidal anti-inflammatory drugs or salts thereof, reconstitutable with specific reconstitution solution and free of buffering agent.